Eli Lilly & Co. stock faces pressure amid pipeline setbacks and GLP-1 competition

Eli Lilly & Co. (ISIN: US5324571083) stock has pulled back from pandemic highs as rivals challenge its weight-loss drug dominance. German-speaking investors watch closely for European reimbursement decisions and supply chain updates. Here's why the NYSE-listed pharma giant remains a key holding.

Eli Lilly & Co. stock has encountered headwinds in recent trading on the New York Stock Exchange (NYSE) in USD, retreating from gains that once topped 400% since early pandemic levels. The primary trigger stems from intensifying competition in the GLP-1 weight-loss drug market, where rivals like Novo Nordisk gain ground with supply expansions and alternative therapies. For DACH investors, this matters now due to Europe's tightening reimbursement frameworks and Lilly's heavy reliance on Mounjaro and Zepbound sales, which face pricing pressures in regulated markets like Germany.

As of: 20.03.2026

By Dr. Elena Voss, Senior Pharma Equity Analyst – Tracking Eli Lilly's innovation edge amid Europe's healthcare cost controls and global obesity treatment shifts.

Recent Market Trigger: GLP-1 Rivalry Heats Up

The Eli Lilly & Co. stock, listed on NYSE in USD, has softened as Novo Nordisk ramps up Wegovy production, eroding Lilly's lead in the booming GLP-1 receptor agonist space. Investors worry about market share erosion after Lilly's latest supply constraints for Zepbound were highlighted in earnings calls. This dynamic unfolded sharply over the past week, with the stock dipping amid broader sector rotation out of high-valuation biopharma names.

Pharma pipelines remain Lilly's core strength, but delays in oral GLP-1 candidates have fueled skepticism. Analysts note that while Mounjaro sales hit record highs last quarter, forward guidance flagged higher R&D spend to counter competition. DACH portfolios heavy in healthcare ETFs feel this pinch, as VanEck Pharmaceuticals and similar funds track Lilly closely.

Market reaction was swift: on NYSE in USD, shares traded in a narrow range reflecting caution ahead of FDA updates on obesity drugs. This isn't panic selling but a recalibration after explosive multi-year gains.

Pipeline Progress and Patent Cliffs Ahead

Lilly's oncology and Alzheimer's portfolios provide diversification beyond diabetes and obesity. Donanemab, the Alzheimer's hopeful, awaits full EMA approval, a process watched keenly by German health authorities focused on dementia care costs. Success here could offset GLP-1 slowdowns, with Phase 3 data showing promising amyloid clearance rates.

However, patent expirations loom for older blockbusters like Humalog insulin, pressuring margins through 2028. Lilly counters with biosimilars defense strategies and next-gen insulins, but generics from Teva and Mylan already bite in Europe. For Austrian and Swiss investors, this translates to vigilant monitoring of IQWiG assessments in Germany, which dictate reimbursement.

Recent trial readouts for Verzenio in breast cancer sustained optimism, boosting trial enrollment in EU sites. Yet, execution risks persist in a high-interest-rate environment squeezing clinical budgets.

Financial Backbone Supports Long-Term Bet

Eli Lilly reported robust revenue growth driven by incretin therapies, with gross margins holding firm above 80% despite manufacturing scale-up costs. Free cash flow generation remains elite among Big Pharma peers, funding a $10 billion share repurchase authorized last year. Debt levels are manageable, with net debt-to-EBITDA under 2x.

Dividend yield on NYSE in USD hovers modestly at 0.7%, prioritizing growth over payouts – a trait appealing to total-return focused DACH funds. Capex surges for new Indiana facilities signal commitment to U.S. supply chain resilience, mitigating tariff risks under potential policy shifts.

Valuation trades at a premium forward P/E of around 45x, justified by 20%+ EPS CAGR projections if pipelines deliver. Peers like Pfizer lag on growth but offer value; Lilly commands the premium for innovation moat.

Risks: Competition, Regulation, and Macro Pressures

Chief among risks is compounded GLP-1 competition from oral peptides and multi-agonists in development at Pfizer and smaller biotechs. Supply shortages persist, with Zepbound waitlists stretching months – a vulnerability rivals exploit. Regulatory hurdles intensify: FDA scrutiny on tirzepatide safety data could cap label expansions.

In Europe, G-BA negotiations in Germany threaten volume-based pricing cuts, squeezing ex-U.S. revenue comprising 40% of total. Inflation Reduction Act caps in the U.S. further cloud Medicare dynamics. Macro headwinds include persistent inflation eroding patient affordability for high-cost therapies.

Patent litigation with HEC Pharma over semaglutide analogs adds uncertainty, potentially unlocking biosimilar entry by 2031. DACH investors must weigh these against Lilly's 50%+ R&D reinvestment rate.

DACH Investor Relevance: Europe Exposure Key

For German, Austrian, and Swiss investors, Lilly's foothold in Europe via German manufacturing sites in Alzey ensures supply stability amid U.S.-EU trade tensions. Reimbursement wins for Mounjaro in Switzerland bolster AWP pricing power. German funds like DWS Top Dividende hold significant stakes, signaling conviction.

Switzerland's private payer market favors Lilly's premium pricing, with obesity prevalence rising 15% post-pandemic. Austria's rising healthcare spend aligns with Lilly's immunology launches. Cross-border tax efficiency via U.S. listings suits institutional DACH allocations.

ETF exposure via iShares MSCI World Health Care provides low-cost entry, but direct NYSE positions via Xetra offer liquidity for retail. Currency hedging mitigates USD-EUR volatility.

Strategic Outlook: Beyond GLP-1 Dominance

Lilly pivots to cardiometabolics and neuroscience, with Retatrutide Phase 3 data expected mid-2026 promising triple-agonist efficacy. Immunology expansions via Omvoh target IBD markets underserved in Europe. Acquisitions like Loxo Oncology bolster precision medicine.

Sustainability initiatives, including carbon-neutral manufacturing by 2035, align with EU Green Deal mandates – a plus for ESG-mandated DACH pensions. Analyst consensus leans buy, with median targets implying 15-20% upside from current NYSE levels in USD.

Long-term, obesity epidemic demographics sustain demand; 1 in 8 Europeans qualify per WHO. Lilly's scale positions it to capture share amid $100 billion addressable market by 2030.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.